CJC NO DAC + IPAMORELIN Pen

CJC‑1295 (No DAC) (Modified GRF 1‑29) is a growth hormone‑releasing hormone (GHRH) analogue engineered to activate the hypothalamic‑pituitary GH axis in a pulsatile fashion. Ipamorelin is a selective ghrelin‑receptor agonist (GHS‑R1a) designed to stimulate growth hormone (GH) release with minimal effects on cortisol or prolactin. When combined, these peptides act through distinct yet complementary pathways to enhance endogenous GH secretion more effectively than either alone.

This synergistic peptide stack is studied in research exploring GH modulation, neuroendocrine signaling, tissue biology, body composition, and recovery mechanisms.

Key Features

🧬 cGMP manufactured in an FDA‑registered facility
📊 ≥98% purity confirmed by HPLC analysis
📄 Batch‑specific Certificates of Analysis (COAs) included
✒️ Pre‑filled sterile peptide pens for research use only

Human-Relevant Research Applications

🔬 Selective GH secretagogue activity — Ipamorelin
Human studies demonstrate that Ipamorelin stimulates GH release via the ghrelin receptor with minimal effects on cortisol or prolactin, making it a highly selective secretagogue for research purposes.
🔗 https://pubmed.ncbi.nlm.nih.gov/10496658/

🔬 Synergistic dual-pathway GH modulation
Mechanistic research shows that combining a GHRH analogue (CJC‑1295 No DAC) with a GHS‑R agonist (Ipamorelin) targets complementary receptors, producing more robust and physiologically pulsatile GH signaling than either agent alone in controlled experimental settings.
🔗 https://peptpedia.org/compare/cjc-1295-vs-ipamorelin

Key Benefits of CJC‑1295 (No DAC) + Ipamorelin

💥 Enhanced Endogenous GH Release – Dual-pathway stimulation amplifies growth hormone secretion compared with single-agent protocols.

🧪 Synergistic Neuroendocrine Action – Targets both GHRH and ghrelin receptors to explore complementary GH axis regulation.

⚖️ Supports Physiological GH Pulsatility – Mimics natural GH release patterns for more realistic research modeling.

🧬 Versatile Research Applications – Enables investigation into GH-mediated effects on body composition, tissue recovery, metabolism, and anabolic signaling.

🔍 Selective Hormone Modulation – Ipamorelin’s receptor specificity minimizes off-target hormone elevations, improving experimental clarity.

Mechanism Summary

• CJC‑1295 (No DAC) binds to GHRH receptors on pituitary somatotrophs, stimulating GH synthesis and release through hypothalamic pathways.
• Ipamorelin binds selectively to the ghrelin receptor (GHS‑R1a), triggering GH release with minimal impact on cortisol and prolactin.
• The combination targets two complementary receptors, providing enhanced pulsatile GH release compared with single-agent use.